FDA/CDC

FDA sends baricitinib application back for revision

Publish date: April 14, 2017
By
Denise Fulton

 

The Food and Drug Administration will not be able to approve a new drug application for baricitinib, a Janus kinase (JAK) inhibitor for moderate to severe rheumatoid arthritis, according to a statement from manufacturer Eli Lilly.

The FDA complete response letter cited the need for additional data to determine the most appropriate doses for the once-daily oral medication and to suss out safety concerns across treatment arms.

“We are disappointed with this action. We remain confident in the benefit/risk of baricitinib as a new treatment option for adults with moderate to severe RA,” Christi Shaw, president of Lilly Bio-Medicines, said in a statement. “We will continue to work with the FDA to determine a path forward and ultimately bring baricitinib to patients in the U.S.”

In the recently published RA-BEAM trial, a manufacturer-sponsored, international, randomized, double-blind, phase III clinical trial involving 1,305 adults with moderate to severe active RA, 70% of patients taking baricitinib plus background therapy with methotrexate met the primary efficacy end point – the proportion of patients at week 12 who showed an ACR 20 response – compared with 40% for placebo (N Engl J Med. 2017;376:652-62).

On Twitter @denisefulton

Recommended Reading

No rise in CV events seen with tocilizumab
MDedge Rheumatology
U.S. chikungunya epidemic would likely put rheumatologists on front line
MDedge Rheumatology
Shingles vaccine deemed effective in people with autoimmune disease
MDedge Rheumatology
Compounding rules challenge practice norms
MDedge Rheumatology
Get ready for cancer immunotherapy-induced rheumatic diseases
MDedge Rheumatology
New antibody shows potential as prognostic marker in early rheumatoid arthritis
MDedge Rheumatology
Stopping TNF inhibitors for pregnancy may invite flares
MDedge Rheumatology
Fatigue in rheumatoid arthritis declines with pedometer use
MDedge Rheumatology
Obesity in women with RA greatly influences CRP levels
MDedge Rheumatology
CCP status doesn’t influence tocilizumab’s effectiveness in RA
MDedge Rheumatology